<DOC>
	<DOCNO>NCT00274690</DOCNO>
	<brief_summary>The primary purpose study determine effective dose NK-1 anti-emetic medication prevent nausea vomit female surgery .</brief_summary>
	<brief_title>Post-Operative Nausea And Vomiting Study In Female Patients</brief_title>
	<detailed_description>A Multicenter , Randomized , Double-blind , Placebo-controlled , Parallel Group , Phase II Study Evaluate Safety Efficacy Oral Dosing GW679769 ( 50 mg 150 mg ) Three Consecutive Days When Administered Single Intravenous Dose Ondansetron Hydrochloride Prevention Post-operative Nausea Vomiting Post-discharge Nausea Vomiting Female Subjects Known Risk Factors Post-operative Nausea Vomiting Who Undergoing Laparoscopic/Laparotomic Surgical Procedures Associated Increased Emetogenic Risk</detailed_description>
	<mesh_term>Nausea</mesh_term>
	<mesh_term>Vomiting</mesh_term>
	<mesh_term>Postoperative Nausea Vomiting</mesh_term>
	<mesh_term>Casopitant</mesh_term>
	<mesh_term>Neurokinin-1 Receptor Antagonists</mesh_term>
	<criteria>Known , specify risk factor PONV ( post operative nausea vomit ) Undergoing gynecologic gallbladder surgery . pregnant breastfeeding postmenopausal</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>January 2017</verification_date>
	<keyword>Neurokinin-1 Receptor Antagonist</keyword>
	<keyword>GW679769</keyword>
	<keyword>Post-operative Nausea</keyword>
	<keyword>NK-1 Receptor Antagonist</keyword>
	<keyword>PONV</keyword>
	<keyword>Post-discharge Nausea Vomiting</keyword>
	<keyword>PDNV</keyword>
	<keyword>Vomiting</keyword>
</DOC>